Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,698 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 1,698 shares of Natera stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $320.99, for a total transaction of $545,041.02. Following the completion of the sale, the chief executive officer directly owned 98,199 shares of the company’s stock, valued at approximately $31,520,897.01. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total value of $819,415.64.
• On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60.
• On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $570,473.10.

Natera Price Performance

NTRA stock opened at $327.67 on Friday. The stock has a market capitalization of $47.23 billion, a price-to-earnings ratio of -240.93 and a beta of 1.54. The company has a 50-day moving average of $291.29 and a two-hundred day moving average of $237.00. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $343.18.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter last year, the company posted ($0.74) earnings per share. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on NTRA. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research note on Friday, August 7th. Leerink Partners set a $330.00 target price on shares of Natera in a research report on Friday, August 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Finally, BTIG Research boosted their price target on shares of Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Institutional Investors Weigh In On Natera

Institutional investors have recently modified their holdings of the business. Trust Co. of Vermont bought a new stake in shares of Natera in the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC bought a new position in Natera during the 2nd quarter worth approximately $30,000. Continuum Advisory LLC bought a new position in Natera during the 2nd quarter worth approximately $33,000. Reflection Asset Management bought a new position in Natera during the 4th quarter worth approximately $29,000. Finally, Rakuten Securities Inc. acquired a new position in Natera during the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.